News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • Global crude rose about 3% to near $109 after US-China talks ended without a joint peace roadmap, stoking supply-disruption concerns.
  • Energy-market volatility rose as broader Middle East tensions stayed unresolved despite a 45-day Israel-Lebanon ceasefire extension.
  • U.S. antitrust authorities opened an inquiry into Arm's CPU licensing to assess potential market monopolization.
  • South Korean regulators launched parallel probes of Arm's local offices.
  • Fitch cut Goldman Sachs BDC's outlook to negative, flagging a thin asset coverage cushion and rising non-accruals.
  • Fitch's action raises credit risk concerns for BDC investors and could pressure leveraged-loan valuations.

Latest Articles

B3 divulga funcionamento da bolsa durante o Carnaval

B3 divulga funcionamento da bolsa durante o Carnaval

A B3 comunicou os horários de operação da bolsa para o período do Carnaval. Não haverá pregão para os mercados de renda variável nos dias 16 (segunda) e 17 (terça). Na Quarta-Feira de Cinzas (18) as negociações ocorrerão em regime de meio período, com horários específicos para pré-abertura, sessão contínua e call de fechamento, além de horários dif…

Stifel Flags Young’s and Fuller's as Top UK Pub Picks as Market Recovers

Stifel Flags Young’s and Fuller's as Top UK Pub Picks as Market Recovers

Stifel identifies the UK pubs sector as undervalued yet fundamentally robust heading into 2026, naming Young & Co’s Brewery and Fuller Smith & Turner as its top stock picks. Both companies receive Buy recommendations - Young’s with a 1,450p target and Fuller’s at 750p - supported by premium estate positioning, freehold-backed balance sheets, margin…

H.C. Wainwright Lifts Biogen Price Target to $228, Citing Pipeline Diversification and Key Clinical Catalysts

H.C. Wainwright Lifts Biogen Price Target to $228, Citing Pipeline Diversification and Key Clinical Catalysts

H.C. Wainwright increased its price target on Biogen to $228 from $194 and reaffirmed a Buy rating, pointing to a broadened drug pipeline across renal, lupus and SMA indications. The firm highlighted the felzartamab AMR program, upcoming LEQEMBI IQLIK PDUFA and SPINRAZA High-Dose adoption as drivers that could shift Biogen's revenue mix despite ong…

Wedbush Starts Coverage on Zura Bio with Outperform, $15 Target

Wedbush Starts Coverage on Zura Bio with Outperform, $15 Target

Wedbush has begun coverage of Zura Bio Ltd. with an Outperform rating and a $15.00 price objective, noting clinical readouts and pipeline progress as key upside drivers. The stock trades well below the target but above InvestingPro's Fair Value estimate, and the company announced a CEO appointment effective January 21, 2026.

Hims & Hers Pulls Compounded GLP-1 Pill, BTIG Keeps Buy Rating

Hims & Hers Pulls Compounded GLP-1 Pill, BTIG Keeps Buy Rating

Hims & Hers Health has stopped offering its recently introduced compounded semaglutide pill following industry and regulatory discussions. The move follows signals from the FDA about enforcement against non-approved GLP-1 drugs. Despite the product withdrawal and a recent share-price decline, BTIG has maintained a Buy rating with a $60 price target…

Wolfe Research Holds Peerperform on PPG as Sales Momentum Offsets EPS Miss

Wolfe Research Holds Peerperform on PPG as Sales Momentum Offsets EPS Miss

Wolfe Research reiterated a Peerperform rating on PPG Industries, citing share-gain momentum driven by new, higher-tech products and expansion into broader end-market packages. The firm sees upside tied to improvements in core end markets such as aerospace and refinish but flagged that broader macroeconomic gains are needed to sustain recent progre…

Jefferies Cuts Molina Healthcare Price Target, Flags Medicaid MLR Risks

Jefferies Cuts Molina Healthcare Price Target, Flags Medicaid MLR Risks

Jefferies lowered its price objective for Molina Healthcare to $139 from $160 and kept a Hold rating, citing concerns around Medicaid medical loss ratio (MLR) in late 2026 tied to the Florida CMS contract. The firm expects 2027 EPS to fall year-over-year but slightly less than prior forecasts as the Florida contract matures. Recent corporate result…

Micron Shares Slip After Samsung Moves Up HBM4 Production Schedule

Micron Shares Slip After Samsung Moves Up HBM4 Production Schedule

Micron Technology shares declined 3.2% after reports that Samsung Electronics will begin large-scale production of next-generation HBM4 memory this month for use in Nvidia’s AI processors. Samsung has reportedly cleared Nvidia’s quality checks and secured purchase orders, timing its output to Nvidia’s Vera Rubin launch plans. The move heightens com…

Leerink Boosts Lantheus Price Target to $94 as Firm Flags 2026 Catalysts

Leerink Boosts Lantheus Price Target to $94 as Firm Flags 2026 Catalysts

Leerink Partners has raised its price target on Lantheus Holdings to $94.00 from $90.00 and kept an Outperform rating ahead of the company's fourth-quarter earnings report scheduled for February 19. The firm updated its model to reflect stronger Pylarify volume trends, progress toward an F-18 formulation and potential 2026 product catalysts, while …